NCT02223923 2025-08-01
Patriot
Royal Marsden NHS Foundation Trust
Phase 1 Unknown
Clinical Trials
198 trialsNCT05763004 2024-10-08
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
ImmunOs Therapeutics AG
Phase 1 Unknown
NCT06199908 2024-07-26
AMT-562 in Patients With Selected Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT05836623 2024-02-28
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Crescendo Biologics Ltd.
Phase 1 Unknown
NCT06281860 2024-02-28
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase 1 Unknown
NCT05971862 2024-02-21
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors
Oscotec Inc.
Phase 1 Unknown
NCT05367232 2024-02-07
A Study of ICP-033 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1 Unknown
NCT06240767 2024-02-05
Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils
Wuxi People's Hospital
Phase 1 Unknown
NCT05291182 2024-02-02
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT06232863 2024-02-02
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Zhuhai Beihai Biotech Co., Ltd
Phase 1 Unknown
NCT05388487 2024-01-16
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
HighField Biopharmaceuticals Corporation
Phase 1 Unknown
NCT06001684 2024-01-03
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1 Unknown
NCT05164458 2023-12-28
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT04739293 2023-12-07
Study of ON 123300 in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Unknown
NCT06154343 2023-12-04
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT05886868 2023-11-29
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
Shanghai Best-Link Bioscience, LLC
Phase 1 Unknown
NCT04190823 2023-11-27
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1 Unknown
NCT04894825 2023-11-27
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 1 Unknown
NCT04375267 2023-11-14
LuPARP
Vastra Gotaland Region
Phase 1 Unknown
NCT04294576 2023-11-09
FIH
BJ Bioscience, Inc.
Phase 1 Unknown
NCT05681000 2023-11-09
Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT06116240 2023-11-03
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04156347 2023-10-31
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
Targeted Therapy Technologies, LLC
Phase 1 Unknown
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT05263180 2023-10-18
A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1 Unknown
NCT05267899 2023-09-26
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
Zhejiang Haichang Biotech Co., Ltd.
Phase 1 Unknown
NCT06047431 2023-09-21
A Study of QL1706H in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT06006793 2023-09-01
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT06019013 2023-08-31
A Study of QLF3108 in Participants With Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT06015269 2023-08-29
Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery
Shanghai Cell Therapy Group Co.,Ltd
Phase 1 Unknown
NCT04280341 2023-08-25
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
Peking University
Phase 1 Unknown
NCT05509985 2023-08-14
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
AskGene Pharma, Inc.
Phase 1 Unknown
NCT04965220 2023-08-09
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05360381 2023-08-08
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05976906 2023-08-04
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Zhejiang University
Phase 1 Unknown
NCT05972460 2023-08-02
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT05884801 2023-08-01
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04856150 2023-07-27
A Study of Q-1802 in Patients With Advanced Solid Tumors
QureBio Ltd.
Phase 1 Unknown
NCT05021367 2023-07-24
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05942378 2023-07-12
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Fudan University
Phase 1 Unknown
NCT05821595 2023-06-27
JYB1907 in Subjects With Advanced Solid Tumors
Jemincare
Phase 1 Unknown
NCT05911984 2023-06-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Unknown
NCT03781219 2023-05-31
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Shanghai Kechow Pharma, Inc.
Phase 1 Unknown
NCT03364400 2023-05-15
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
Vigeo Therapeutics, Inc.
Phase 1 Unknown
NCT05848999 2023-05-12
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University
Phase 1 Unknown
NCT05498519 2023-05-11
A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Unknown
NCT05848466 2023-05-08
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Unknown
NCT05818917 2023-04-19
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05810103 2023-04-12
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05171790 2023-04-07
A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown